Table 3.
Examples of compounds identified from individual screening campaigns using the analysis protocol illustrated in Figure 2
| Classification | SID | Target symbol, (species) | SID efficacy | Potency (µM) |
|---|---|---|---|---|
| Functionally Active | 856021 | 5-HT(1A), (Hs) | Agonist | EC50 = 0.018 |
| 22409370 | S1P4R, (Hs) | Antagonist | IC50 = 0.168 | |
| 85285486 | M5R, (Hs) | Allosteric modulator | EC50 = 1.161 | |
| Target Selective (*, probe) | 24428139* | FPR1, (Hs) | Antagonist | Ki = 0.3 |
| 22413249* | NPY-Y2R, (Hs) | Antagonist | IC50 = 3.917 | |
| 4258673* | S1P1R, (Hs) | Agonist | AC50 = 0.207 | |
| Unselective OR Artifact | 17415263 | M1R, (Rn) | Antagonist | AC50 = 3.9811 |
| 85200865 | AVPR1A, (Hs) | Agonist | EC50 = 2.325 | |
| 11532956 | RXFP2, (Hs) | Agonist | AC50 = 0.9742 |
Note: Hs, Homo sapiens; Rn, Rattus norvegicus; Ki, absolute inhibition constant; AC50, potency, concentration at which compound exhibits half maximal efficacy; EC50, half maximal effective concentration.